Preparation and Properties of Alpha1‐Proteinase Inhibitor Concentrate from Human Plasma
Preparation and Properties of Alpha1‐Proteinase Inhibitor Concentrate from Human Plasma
复制标题
人血浆α1-蛋白酶抑制剂浓缩物的制备及性质
作者：
M. Coan;W. J. Brockway;H. Eguizabal;T. Krieg;M. Fournel
抽象的。α 1-蛋白酶抑制剂（α1-PI）已制备为浓缩物，其量足以用于临床测试其治疗肺气肿和其他疾病的安全性和有效性。通过聚乙二醇沉淀和DEAE-Sepharose色谱法从Cohn级分IV-I糊剂中纯化α1-PI。纯化中使用的方法温和，所得产物的行为与血浆中的α1-PI几乎相同。该蛋白质经过热处理（60°C，10小时），以降低血浆传播疾病的风险。这导致蛋白质的一些聚集，但不引起新抗原位点的产生。动物半衰期研究表明，该蛋白表现正常（分解代谢t1/2为68 h）。
Abstract. Alpha1‐proteinase inhibitor (α1‐PI) has been prepared as a concentrate in quantities large enough for clinical testing of its safety and efficacy in the treatment of emphysema and other disorders. The α1‐PI was purified from Cohn fraction IV‐—I paste by polyethylene glycol precipitation and DEAE‐Sepharose chromatography. The methods used in the purification are gentle and the resulting product behaves almost identically to the α1‐PI from plasma. The protein has been heat treated (60°C, 10 h) to lower the risk of transmission of plasma‐borne diseases. This resulted in some aggregation of the protein, but did not cause the generation of new antigenic sites. Half‐life studies in animals showed that the protein behaved normally (catabolic t1/2 of 68 h).
影响因子：
15.9
作者：
COCHRANE, CG;SPRAGG, R;REVAK, SD
通讯作者：
REVAK, SD